Tillomed Laboratories Limited Pharmaceutical Import Profile — United Kingdom (DGFT 2022–2026)

Name: Tillomed Laboratories Limited Pharmaceutical Import Records from India — 13 Products, $16.6M FOB USD (DGFT 2022–2026)
Creator: TransData Nexus

Suresh Sormare

Explore

Tillomed Laboratories Limited — Pharmaceutical Importer Profile (2026) | 13 Products, $16.6M Trade | TransData Nexus

Tillomed Laboratories Limited

Pharmaceutical Importer · United Kingdom · Immunosuppressants Focus · $16.6M Total Trade · DGFT Verified

Tillomed Laboratories Limited is a pharmaceutical importer based in United Kingdom with a total trade value of $16.6M across 13 products in 6 therapeutic categories. Based on 487 verified import shipments from Indian Customs (DGFT) records, Tillomed Laboratories Limited is the #1 buyer in 2 products including Amphotericin, Carmustine. Tillomed Laboratories Limited sources from 11 verified Indian suppliers, with Emcure Pharmaceuticals Limited accounting for 58.9% of imports.

Tillomed Laboratories Limited — Import Portfolio & Supplier Network

Tillomed Laboratories Limited import network — 13 products from Indian suppliers. Source: Indian Customs (DGFT).

Who Are the Verified Indian Suppliers to Tillomed Laboratories Limited?

Customs-verified supplier relationships from Indian DGFT records

Supplier	Value	Shipments	Share
Emcure Pharmaceuticals Limited	$8.1M	368	58.9%
Apex Laboratories Private Limited	$1.7M	39	12.2%
Prosfora Technologies Private Limited

What Formulations Does Tillomed Laboratories Limited Import?

Formulation	Value	Ships
Pharmaceutical products- azathioprine	$501.9K	12
Levosimendan tillomed 2.5 MG/ML	$342.7K	10
Levosimendan injection 2.5 MG/ML	$289.5K	6
Duloxetine 30MG capsule 4x7 cap Each	$274.4K	10
Pharmaceutical products- loperamide	$261.9K	6
Mycophenolate mofetil 500MG- 5x10 TAB	$250.0K	5
Tamoxifen tablets BP 20MG	$245.8K	7
Pharmaceutical finish formulation-	$238.9K	7
Gabapentin tillomed 100MG hard	$200.4K	6
Gabapentin 300MG cap 10x10c	$200.0K	4
Midodrine 2.5MG tablet- 10x10 TAB	$185.6K	5
Mefenamic acid 500MG film coated	$150.0K	3
Amphotericin b liposome for injection	$150.0K	5
Duloxetine 60MG capsule 4x7 cap Each	$142.6K	6
Nitro 100MG capsule- 3x10 cap Each CAPS	$132.5K	4

Tillomed Laboratories Limited imports 282 distinct pharmaceutical formulations. Showing top 15 by value. For full formulation-level data, contact TransData Nexus.

Import Portfolio — Top 13 by Import Value

#	Product	Category	Value	Ships	Share	Rk
1	Mycophenolate	Immunosuppressants	$4.6M	109	0.7%	10
2	Melphalan	Advanced Oncology	$2.7M	78	12.2%	2
3	Amphotericin	Antifungals	$2.5M	49	0.7%	1
4	Azathioprine	Immunosuppressants	$2.0M	43	2.1%	8
5	Busulfan	Advanced Oncology	$1.0M	47	12.6%	2
6	Carmustine	Advanced Oncology	$900.0K	18	3.6%	1
7	Nitrofurantoin	Advanced Antibiotics	$646.0K	25	1.9%	10
8	Amikacin	Advanced Antibiotics	$550.0K	11	2.6%	4
9	Loperamide	Gastrointestinal	$489.8K	28	0.6%	14
10	Leflunomide	Immunosuppressants	$466.4K	48	1.7%	13
11	Tamoxifen	Advanced Oncology	$404.1K	14	2.7%	7
12	Dapsone	Antimalarial & Antiparasitic	$291.0K	15	0.9%	11
13	Cabazitaxel	Advanced Oncology	$100.0K	2	1.1%	12

Tillomed Laboratories Limited imports 13 pharmaceutical products across 6 categories into United Kingdom totaling $16.6M. The company is the #1 buyer for 2 products: Amphotericin, Carmustine.

Tillomed Laboratories Limited — Corporate Profile & Information

Company type, headquarters, distribution network, and industry role

1Company Overview

Tillomed Laboratories Limited is a UK-based pharmaceutical company specializing in the licensing, marketing, and supply of generic and branded pharmaceutical products. Established on 28 September 1990, the company is headquartered at 220 Butterfield, Great Marlings, Luton, Bedfordshire, LU2 8DL, England. Tillomed operates as a private limited company and is a subsidiary of Emcure Pharmaceuticals, a leading Indian pharmaceutical firm with a global presence.

The company focuses on providing cost-effective and timely access to a comprehensive range of medicines across various therapeutic areas. Tillomed's operations encompass the entire supply chain, from sourcing and importing pharmaceutical products to distribution within the United Kingdom. This integrated approach enables the company to meet the needs of hospitals, wholesalers, and pharmacists nationwide.

2Distribution Network

Tillomed Laboratories Limited's distribution network is strategically designed to ensure efficient delivery of pharmaceutical products across the United Kingdom. While specific warehouse locations are not publicly disclosed, the company's headquarters in Luton serves as a central hub for its operations. The logistics capabilities are tailored to handle a diverse portfolio of pharmaceutical products, ensuring compliance with regulatory standards and timely distribution. The geographic coverage primarily focuses on the UK market, with potential expansion into other European regions, leveraging the company's subsidiaries in France, Spain, Germany, Italy, and the Czech Republic.

3Industry Role

In the United Kingdom's pharmaceutical supply chain, Tillomed Laboratories Limited functions as a primary wholesaler and distributor. The company imports a wide array of pharmaceutical products, including both generic and branded medicines, and supplies them to hospitals, wholesalers, and pharmacists. This role positions Tillomed as a critical intermediary between manufacturers and end-users, ensuring the availability of essential medicines throughout the UK. The company's operations are characterized by a focus on cost-effectiveness and timely delivery, aligning with the needs of the healthcare sector.

TransData Nexus Research · Company registries, industry databasesMar 2026

Supplier Relationship Intelligence — Tillomed Laboratories Limited

Sourcing concentration, supply chain resilience, and strategic implications

1Sourcing Concentration Analysis

Tillomed Laboratories Limited's sourcing strategy exhibits a significant concentration on a select group of suppliers, particularly from India. The company's total import value from India amounts to $16.6 million USD, distributed across 487 shipments and 13 products spanning six therapeutic categories. The top five imported products—Mycophenolate, Melphalan, Amphotericin, Azathioprine, and Busulfan—collectively account for 76.8% of the total import value. This concentration indicates a strategic focus on specific high-demand products, potentially leveraging favorable pricing and supply chain efficiencies.

The reliance on a limited number of suppliers, such as Emcure Pharmaceuticals Limited, which accounts for 58.9% of the total import value, suggests a strong partnership and possibly favorable contractual terms. However, this dependency also introduces risks related to supply chain disruptions, regulatory changes, or geopolitical factors affecting the supplier's operations. Diversifying the supplier base could mitigate these risks and enhance supply chain resilience.

2Supply Chain Resilience

Tillomed Laboratories Limited's supply chain resilience is influenced by its sourcing practices, particularly the heavy reliance on a few key suppliers from India. While this strategy may offer cost advantages and streamlined logistics, it also exposes the company to potential disruptions. The absence of publicly available information regarding backup suppliers and the diversity of formulations imported indicates a need for strategic planning to enhance supply chain robustness. Engaging with multiple suppliers and diversifying the product portfolio could strengthen the company's ability to withstand supply chain challenges.

Importing Pharmaceuticals into United Kingdom — Regulatory Framework

Regulatory authority, GMP requirements, import licensing for United Kingdom

1Regulatory Authority & Framework

The Medicines and Healthcare products Regulatory Agency (MHRA) is the primary regulatory authority overseeing pharmaceutical imports into the United Kingdom. MHRA is responsible for ensuring that medicines meet appropriate standards of safety, quality, and efficacy. Key legislation governing pharmaceutical imports includes the Medicines for Human Use (Clinical Trials) Regulations 2004 and the Medicines Act 1968. These regulations outline requirements for marketing authorizations, manufacturing licenses, and importation procedures. (cms.mhra.gov.uk)

The marketing authorization pathway for Indian generics involves obtaining a Marketing Authorization (MA) license from MHRA. This process includes submitting comprehensive data on the product's quality, safety, and efficacy. Additionally, a Qualified Person (QP) must certify that the product has been manufactured and tested according to the MA and Good Manufacturing Practice (GMP) standards. MHRA conducts inspections of manufacturing sites to ensure compliance with GMP requirements. (gov.uk)

2Import Licensing & GMP

To import human medicines into the UK, companies must obtain a Wholesale Distribution License (WDA(H)) from MHRA. This license authorizes the holder to import, store, and distribute medicines within the UK. For importing unlicensed medicines, a Manufacturer's "Specials" License (MSL) is required. The manufacturing site must hold a valid GMP certificate, which can be from EU GMP, WHO GMP, or PIC/S standards. MHRA recognizes GMP certificates from countries with equivalent standards, facilitating the importation of medicines from approved countries. (gov.uk)

Tillomed Laboratories Limited — Procurement Pattern Analysis

Product strategy, sourcing profile, and market positioning

1Product Strategy

Tillomed Laboratories Limited's product strategy focuses on specific therapeutic areas, including immunosuppressants, advanced oncology, and antifungals. The company's imports from India reflect this focus, with the top five products—Mycophenolate, Melphalan, Amphotericin, Azathioprine, and Busulfan—collectively accounting for 76.8% of the total import value. This strategy aligns with market demand for specialized treatments in these areas, catering to the needs of hospitals and healthcare providers in the UK.

2Sourcing Profile

Tillomed Laboratories Limited's sourcing strategy emphasizes generic drug procurement, particularly from India, which is known for its robust pharmaceutical manufacturing capabilities. The company's focus on finished pharmaceutical formulations, such as tablets, capsules, syrups, and injections, indicates a preference for ready-to-use products that meet regulatory standards. India's compliance with international GMP standards and its cost-effective manufacturing processes make it a strategic partner for Tillomed's procurement needs.

3Market Positioning

Based on its product mix, Tillomed Laboratories Limited serves the hospital and wholesale distribution segments of the UK market. The company's focus on specialized therapeutic areas and its role as a primary wholesaler position it to meet the needs of healthcare providers requiring cost-effective and timely access to essential medicines. This market positioning aligns with the company's mission to deliver effective, high-quality, and sustainable healthcare solutions.

Seller's Guide — How to Become a Supplier to Tillomed Laboratories Limited

Opportunity assessment, qualifications, and practical approach strategy

1Opportunity Assessment

There is a realistic opportunity for new Indian suppliers to engage with Tillomed Laboratories Limited, particularly in the therapeutic areas of immunosuppressants, advanced oncology, and antifungals. The company's concentrated sourcing pattern suggests potential gaps in its supplier base that could be addressed by offering alternative products within these categories. Establishing partnerships with Tillomed could enhance supply chain diversity and resilience, benefiting both parties.

2Requirements & Qualifications

Indian exporters seeking to supply Tillomed Laboratories Limited and the UK market must ensure compliance with MHRA's regulatory requirements. This includes obtaining appropriate marketing authorizations, ensuring manufacturing sites hold valid GMP certificates recognized by MHRA, and adhering to labeling and packaging standards. Additionally, products must meet quality standards, including batch testing and stability requirements, to ensure safety and efficacy

TransData Nexus Research · Industry procurement practicesMar 2026

Frequently Asked Questions — Tillomed Laboratories Limited

What products does Tillomed Laboratories Limited import from India?

Tillomed Laboratories Limited imports 13 pharmaceutical products across 6 categories. Top imports: Mycophenolate ($4.6M), Melphalan ($2.7M), Amphotericin ($2.5M), Azathioprine ($2.0M), Busulfan ($1.0M).

Who supplies pharmaceuticals to Tillomed Laboratories Limited from India?

Tillomed Laboratories Limited sources from 11 verified Indian suppliers. The primary supplier is Emcure Pharmaceuticals Limited (58.9% of imports, $8.1M).

What is Tillomed Laboratories Limited's total pharmaceutical import value?

Tillomed Laboratories Limited's total pharmaceutical import value from India is $16.6M, based on 487 verified shipments in Indian Customs (DGFT) data.

What therapeutic categories does Tillomed Laboratories Limited focus on?

Tillomed Laboratories Limited imports across 6 categories. The largest: Immunosuppressants (42.3%), Advanced Oncology (31.0%), Antifungals (14.8%).

Get Full Tillomed Laboratories Limited Import Intelligence

Access shipment-level details, supplier connections, pricing data, and competitive analysis. TransData Nexus provides verified Indian Customs (DGFT) data trusted by pharmaceutical trade professionals worldwide.

Contact for Data Access Request Live Demo

Official References & Regulatory Resources

Verify import regulations and drug registration requirements with the agencies above.

Research Methodology & Data Transparency

Suresh Sormare

Verified Author

Pharmaceutical Export-Import Analyst & Trade Intelligence Expert

Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.

linkedin.com/in/sureshsormare

Primary Data Source

All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.

Data Source & Methodology

Trade data sourced from Indian Customs (DGFT) export shipment records. Values represent FOB export value in USD. Profile aggregates 6 company name variants from customs records. For current shipment-level data, contact TransData Nexus.